Novartis AG Triumphs in the Journey to Protect Vildagliptin Patent in Vietnam

Novartis AG, a leading global pharmaceutical corporation, holds the patent for the active ingredient “Vildagliptin”, a crucial component in the treatment of type 2 diabetes. In Vietnam, this groundbreaking invention is protected under Patent No. 5529. Soon after, counterfeit products emerged in the market, significantly cheaper than the genuine product, causing confusion among consumers. Novartis AG did not stand idly by. Extensive investigative efforts revealed the reality: Novartis AG’s patented product was being severely infringed upon in Vietnam....